Target intelligence / Profile preview

Non-FASN off-target mRNAs with seed-region complementarity

Molecular classification
mRNA
01

Overview

Non-FASN off-target mRNAs with seed-region complementarity refers to a collective group of messenger RNA (mRNA) transcripts that are unintentionally downregulated by RNA interference (RNAi) or antisense therapies designed to target Fatty Acid Synthase (FASN). This phenomenon, known as seed-mediated off-target effects, occurs when the seed region of an siRNA—typically nucleotides 2 through 8—shares complementarity with the 3' untranslated regions (UTRs) of transcripts other than the intended FASN target, mimicking the natural regulatory mechanism of microRNAs (Jackson et al., 2003, Nature Biotechnology). These interactions can lead to significant changes in the cellular transcriptome, potentially causing unintended toxicity or confounding the interpretation of biological data during drug development (Birmingham et al., 2006, Nature Methods). Because FASN is a major therapeutic target in oncology and metabolic diseases like NASH, ensuring the specificity of nucleic acid-based inhibitors is a critical safety requirement. These off-target mRNAs do not constitute a single therapeutic target but rather represent a technical and safety challenge that must be managed through sequence optimization and rigorous transcriptomic screening. Consequently, they are classified as an incorrect target entry in a therapeutic context, as they are entities to be avoided rather than modulated for clinical benefit.

Other names
Seed-mediated off-targetsRNAi off-target transcriptsmiRNA-like off-target effectsNon-specific mRNA knockdown
02

Mechanism of action

Sequence-specific binding of an siRNA or ASO seed region (typically nucleotides 2-8) to the 3' untranslated region (UTR) of unintended mRNAs, leading to RISC-mediated degradation or translational repression.

03

Biological functions

Protein translationGene expression regulation
04

Disease associations

Drug-induced toxicityOff-target phenotypic effects
05

Safety considerations

Unintended gene silencingCellular toxicityFalse-positive results in functional genomicsHepatotoxicity in oligonucleotide therapeutics
06

Interacting drugs

FASN-targeting siRNAs

2 more in the full profile.

07

Biomarkers

Transcriptome profiling (RNA-seq)Microarray analysisReporter gene assays

Beyond the preview

Go deeper on Non-FASN off-target mRNAs with seed-region complementarity.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Non-FASN off-target mRNAs with seed-region complementarity.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call